Video

Dr. Hofman on the potential of LuPSMA in advanced prostate cancer

Author(s):

Urology Times staff

“We expect an outcome from the FDA next year and if that's positive, we expect global, widespread availability of this as a new option for men with metastatic castration-resistant prostate cancer,” says Michael S. Hofman, MBBS (Hons), FRACP, FAANMS, FICIS.

In this video, Michael S. Hofman, MBBS (Hons), FRACP, FAANMS, FICIS, discusses the main points of the lecture, “LuPSMA: The Newest Treatment Class for Advanced Prostate Cancer,” presented recently at the 2021 Prostate Cancer Foundation Scientific Retreat.

The FDA is currently reviewing a new drug application (NDA) for the targeted radioligand therapy 177Lu-PSMA-617 (LuPSMA) for the treatment of patients with metastatic castration-resistant prostate cancer in the post androgen receptor pathway inhibition, post taxane-based chemotherapy setting. A decision on the NDA is scheduled to be made in the first half of 2022.

Hofman is a nuclear medicine physician and director of PROSTIC, Melbourne, Australia.

Related Videos
Raveen Syan, MD, FPMRS, answers a question during a video interview
J. Quentin Clemens, MD, MSCI, answers a question during a video interview
Timothy Lyon, MD, answers a question during a video interview
Anne Pelletier Cameron, MD, FRCSC, FPMRS, answers a question during a video interview
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Related Content
FDA fast tracks 64Cu-SAR-bisPSMA for biochemically recurrent prostate cancer
January 24th 2025

FDA fast tracks 64Cu-SAR-bisPSMA for biochemically recurrent prostate cancer

Hannah Clarke
64Cu-SAR-bisPSMA was previously granted a fast track designation in August 2024 for PET imaging of PSMA-positive prostate cancer lesions in patients with suspected metastasis who are candidates for initial definitive therapy.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023

Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer

Urology Times staff
"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
Illuccix approved in Europe for detection of PSMA-positive lesions
January 17th 2025

Illuccix approved in Europe for detection of PSMA-positive lesions

Hannah Clarke
The European approval of Illuccix adds on to prior approvals in the US, Australia, and Canada.
Addition of PSMA PET led to notable stage migration in mHSPC, study shows
January 16th 2025

Addition of PSMA PET led to notable stage migration in mHSPC, study shows

Hannah Clarke
In total, 40.3% of patients experienced a change in staging between initial assessment on conventional imaging and PSMA PET.
Conventional imaging may understage prostate cancer, new data suggest
January 3rd 2025

Conventional imaging may understage prostate cancer, new data suggest

Hannah Clarke
“However, it was informative to uncover such a high number of metastatic findings in a well-defined cohort of patients resembling the EMBARK trial population that was supposed to only include those without metastases," says Adrien Holzgreve, MD, MHA.
[99mTc]Tc-HYNIC-iPSMA shows promise in prostate cancer imaging
January 3rd 2025

[99mTc]Tc-HYNIC-iPSMA shows promise in prostate cancer imaging

Hannah Clarke
The detection rate for [99mTc]Tc-HYNIC-iPSMA SPECT imaging was 77.5%.
© 2025 MJH Life Sciences

All rights reserved.